Atorvastatin.

Area of Science:

• Cardiovascular Pharmacology
• Lipid Metabolism Disorders

Background:

• Atorvastatin is a highly effective 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin).
• It is recognized for its potency in reducing low-density lipoprotein (LDL) and total cholesterol levels.
• It was the first statin demonstrated to lower triglycerides in patients with isolated hypertriglyceridaemia.

Purpose of the Study:

• To review the efficacy and safety profile of atorvastatin.
• To highlight its lipid-lowering and non-lipid-lowering effects.
• To discuss current clinical trial evidence and ongoing research.

Main Methods:

• Review of existing clinical trial data and pharmacological properties of atorvastatin.
• Analysis of its impact on lipid profiles, including LDL cholesterol and triglycerides.
• Examination of non-lipid-related effects such as endothelial function, smooth muscle proliferation, platelet aggregation, and inflammation.

Main Results:

• Atorvastatin demonstrates significant potency in lowering LDL and total cholesterol.
• It is effective in reducing triglycerides in patients with isolated hypertriglyceridaemia.
• Observed non-lipid effects include improved endothelial function, antiproliferative actions, reduced platelet aggregation, anti-inflammatory properties, and potential plasma glucose reduction.

Conclusions:

• Atorvastatin is a safe and effective statin with robust lipid-lowering capabilities.
• Its non-lipid-lowering effects contribute to its overall cardiovascular benefits.
• Further clinical trial evidence is anticipated to further define its therapeutic role.